RESUMO
We aimed to evaluate the predictors of subsequent development of postpartum carbohydrate intolerance, metabolic syndrome and cardiovascular risk factors in women with previous GDM. Two hundred fifty-two consecutive women with GDM were enrolled. After exclusion of women who did not attend to the hospital for follow-up visits for minimum 1 year, data of 195 patients were evaluated. Seventy-one lean women with negative screening for GDM were included as a control group. The prevalence of diabetes, impaired glucose tolerance and impaired fasting glucose and metabolic syndrome was significantly higher in women with previous GDM than healthy controls. Women with previous GDM were more insulin resistant, had an atherogenic lipid profile and increased carotid IMT. The most important predictors of postpartum diabetes were the need for insulin treatment during index pregnancy and glucose values on antepartum OGTT. Among women with previous GDM, the development of postpartum diabetes and metabolic syndrome was associated with increased carotid IMT. Our data show that women with previous GDM are at high risk for developing carbohydrate intolerance, metabolic syndrome and atherosclerosis. Antepartum prediction of high risk subjects for the subsequent development of postpartum carbohydrate intolerance and metabolic syndrome seems to be vital to prevent cardiovascular outcomes.
Assuntos
Doenças Cardiovasculares/metabolismo , Diabetes Gestacional/metabolismo , Intolerância à Glucose/metabolismo , Período Pós-Parto/metabolismo , Adulto , Índice de Massa Corporal , Doenças Cardiovasculares/epidemiologia , Doenças Cardiovasculares/etiologia , Doenças das Artérias Carótidas/etiologia , Doenças das Artérias Carótidas/metabolismo , Diabetes Mellitus Tipo 2/complicações , Diabetes Mellitus Tipo 2/epidemiologia , Diabetes Mellitus Tipo 2/metabolismo , Diabetes Gestacional/sangue , Diabetes Gestacional/epidemiologia , Feminino , Intolerância à Glucose/complicações , Intolerância à Glucose/epidemiologia , Humanos , Lipídeos/sangue , Síndrome Metabólica/complicações , Síndrome Metabólica/epidemiologia , Síndrome Metabólica/metabolismo , Gravidez , Prevalência , Fatores de Risco , Túnica Íntima/metabolismoRESUMO
OBJECTIVE: The aim of this prospective study was to investigate the effect of LT4 suppression therapy on plasma thrombin activatable fibrinolysis inhibitor (TAFI) antigen and plasminogen activator inhibitor-1 (PAI-1) levels in benign thyroid nodules. We also compared hyperthyroid patients and healthy controls. SUBJECTS AND METHODS: Twenty premenopausal women with benign thyroid nodules were given LT4 suppression therapy for 1 year. Plasma TAFI and PAI-1 antigen levels were measured at baseline and after LT4 suppression treatment. The endogenous hyperthyroid group was composed of 19 premenopausal females with newly diagnosed endogenous hyperthyroidism. Eighteen age-matched euthyroid healthy premenopausal women were enrolled as the control group. RESULTS: TAFI antigen levels decreased after LT4 suppression treatment; however, the difference was not statistically significant (p = 0.057). LT4 treatment resulted in a nonsignificant increase in PAI-1 levels. Patients with endogenous hyperthyroidism had decreased levels of TAFI antigen and increased levels of PAI-1 antigen (p < 0.05). There was a negative correlation between the FT(4) and TAFI antigen levels. Serum TSH was positively correlated with the plasma levels of TAFI antigen. CONCLUSION: LT4 suppression therapy for benign thyroid nodules did not result in a significant decrease in TAFI antigen levels in premenopausal women, but endogenous hyperthyroidism was associated with significantly decreased levels of TAFI antigen.
Assuntos
Carboxipeptidase B2/sangue , Bócio Nodular/sangue , Bócio Nodular/tratamento farmacológico , Nódulo da Glândula Tireoide/sangue , Nódulo da Glândula Tireoide/tratamento farmacológico , Tiroxina/farmacologia , Adulto , Análise de Variância , Antígenos/sangue , Carboxipeptidase B2/imunologia , Estudos de Casos e Controles , Ensaio de Imunoadsorção Enzimática , Feminino , Bócio Nodular/diagnóstico por imagem , Humanos , Hipertireoidismo , Pessoa de Meia-Idade , Inibidor 1 de Ativador de Plasminogênio/sangue , Inibidor 1 de Ativador de Plasminogênio/imunologia , Pré-Menopausa , Estudos Prospectivos , Nódulo da Glândula Tireoide/diagnóstico por imagem , Tiroxina/sangue , Tri-Iodotironina/sangue , UltrassonografiaRESUMO
BACKGROUND: Paraoxonase-1 (PON-1) may play an important role in atherosclerosis. Atherosclerosis is an inflammatory disease and C-reactive protein is a marker for inflammation. The aim of this study was to determine serum PON-1 activity and high-sensitivity C-reactive protein (hs-CRP) levels and assess carotid intima-media thickness, a marker of early atherosclerotic changes, in patients with subclinical hypothyroidism. MATERIAL/METHODS: hs-CRP concentrations and PON-1 activity with respect to carotid intima-media thickness were evaluated in 38 subclinical hypothyroidism patients (normolipidemic, mean age: 49.79+/-10.04 years) before and after 3 months of stable euthyroidism and compared with those of 19 euthyroid normolipidemic healthy individuals (mean age: 49.95+/-8.12 years). RESULTS: At baseline, the patients with subclinical hypothyroidism had similar levels of PON-1 activity and hs-CRP and a similar lipid profile as the controls; however, the carotid intima-media thickness was greater than in the controls. Levothyroxine treatment had no effect on serum PON-1 activity and hs-CRP level, but it resulted in a significant reduction in carotid intima-media thickness in the subclinical hypothyroidism patients. CONCLUSIONS: PON-1 activity and hs-CRP levels did not significantly differ between subclinical hypothyroid patients and controls. Although levothyroxine treatment might have the potential to reverse the progression of atherosclerosis in subclinical hypothyroid patients, PON-1 activity and hs-CRP levels were not affected by this treatment. The reduction in carotid intima-media thickness was independent of the decrease in serum lipid profile or other variables.
Assuntos
Arildialquilfosfatase/sangue , Proteína C-Reativa/metabolismo , Terapia de Reposição Hormonal/métodos , Hipotireoidismo/tratamento farmacológico , Tiroxina , Túnica Íntima/patologia , Adulto , Análise Química do Sangue , Índice de Massa Corporal , Pesos e Medidas Corporais , Artérias Carótidas/diagnóstico por imagem , Humanos , Hipotireoidismo/sangue , Hipotireoidismo/enzimologia , Hipotireoidismo/patologia , Pessoa de Meia-Idade , Estatísticas não Paramétricas , UltrassonografiaRESUMO
OBJECTIVE: Obesity has been suggested as an independent risk factor for cardiovascular disease. Increasing evidence shows that engagement of soluble CD40 ligand (sCD40L) with its receptor plays a crucial role in the pathogenesis of atherosclerosis. The aim of the present study was to test whether obesity is associated with low-grade systemic inflammation as measured by serum high-sensitive C-reactive protein (hsCRP) and sCD40L concentration. METHODS: Serum hsCRP and sCD40L concentrations were measured in 148 nondiabetic people. The participants were divided into three groups depending upon their body mass index (BMI) levels: Group 1 (normal weight), BMI<25 kg/m(2); Group 2 (overweight), BMI 25 kg/m(2) to 29.9 kg/m(2); and Group 3 (obese), BMI>or=30 kg/m(2). RESULTS: Obese people had more elevated hsCRP levels than both their normal weight and overweight counterparts (P=0.000 and P=0.000, respectively). Similarly, serum concentrations of sCD40L were significantly higher, statistically, in obese subjects compared with normal weight subjects (P=0.003). In addition, obese subjects had higher values of sCD40L than overweight subjects, but the difference did not reach statistical significance (P=0.063). The levels of high-density lipoprotein cholesterol were significantly lower in obese subjects compared to normal weight subjects (P=0.048). The analysis of platelet count disclosed a statistically significant difference between obese subjects and normal weight subjects (P=0.028). The levels of BMI were positively correlated with the serum levels of hsCRP and sCD40L in all subjects (r=0.514, P=0.000 and r=0.283, P=0.000, respectively). Levels of hsCRP were positively correlated with waist circumference, fasting glucose, total cholesterol, triglyceride, low-density lipoprotein cholesterol, leukocytes, platelets, systolic and diastolic blood pressure. Similarly, soluble CD40L levels were positively correlated with waist circumference, fasting glucose and leukocytes. CONCLUSION: Obese patients showed a significant increase of hsCRP and sCD40L levels compared with normal weight subjects, which might contribute to the known proinflammatory milieu found in these patients.
Assuntos
Proteína C-Reativa/análise , Ligante de CD40/sangue , Obesidade/sangue , Sobrepeso/sangue , Adulto , Idoso , Idoso de 80 Anos ou mais , Índice de Massa Corporal , Feminino , Humanos , Masculino , Pessoa de Meia-IdadeRESUMO
BACKGROUND: The prevalence of thyroid cancer in renal transplant population has not been widely studied, and there is no consensus on the management of thyroid cancer in transplant patients. The aim of this study was to evaluate changes in thyroid hormone levels and investigate the incidence of the thyroid cancer after renal transplantation. MATERIALS AND METHODS: From October 1989 to April 2007, 122 renal allograft recipients that were being followed underwent thyroid ultrasonography to determine nodules together with thyroid hormone levels. Ultrasound-guided fine-needle aspiration biopsy (FNAB) was performed to the nodules > 10 mm or those with 8-10 mm diameter but with calcifications. RESULTS: One hundred and eight patients (88.5%) had normal thyroid function. None of the patients had overt hypothyroidism, 2 had subclinical hypothyroidism, 10 subclinical thyrotoxicosis, and 2 low T3 syndrome. Mean thyroid volume was 14.2 +/- 7.2 ml. In all, 91.8% was diagnosed with goiter (n = 112). Seventy-two thyroid nodules were detected in 49 kidney allograft recipients (single nodule in 30, multiple in 19 patients). Eighty-four biopsy samples were reported as benign (n = 21, 87.5%), 8 as suspicious (n = 2, 8.3%), and 4 as inadequate (n = 1, 4.1%). After surgery, one of the patients (0.8%) with suspicious FNAB was reported as papillary thyroid carcinoma. CONCLUSION: Because of the high incidence of thyroid dysfunction in transplant patients, screening of thyroid function should be a part of follow-up. Our results suggest that although frequency of nodules is increased in kidney transplant patients, prevalence of thyroid cancer is slightly, but not significantly, higher than that of the normal population.
Assuntos
Transplante de Rim/efeitos adversos , Doenças da Glândula Tireoide/epidemiologia , Adulto , Idoso , Biomarcadores/sangue , Biópsia por Agulha Fina , Estudos Transversais , Feminino , Humanos , Incidência , Masculino , Pessoa de Meia-Idade , Prevalência , Medição de Risco , Estatísticas não Paramétricas , Doenças da Glândula Tireoide/patologia , Testes de Função Tireóidea , Neoplasias da Glândula Tireoide/epidemiologia , Neoplasias da Glândula Tireoide/patologia , Turquia/epidemiologia , Ultrassonografia de IntervençãoRESUMO
OBJECTIVE: Endogenous hyperthyroidism is associated with altered coagulation. The aim of the present study is to investigate the effect of levothyroxine (LT(4)) suppression treatment for benign thyroid nodules on coagulation system. DESIGN: Prospective case-control study. Patients Thirty consecutive euthyroid pre-menopausal women with nodular goitre disease and 28 healthy controls were included in the study. MEASUREMENTS: Plasma fibrinogen, d-dimer, von Willebrand factor (vWF), tissue factor (TF), tissue plasminogen activator (tPA), plasminogen activator inhibitor (PAI-1) and tissue factor pathway inhibitor (TFPI) levels were measured at baseline and after LT(4) suppression therapy. RESULTS: Plasma levels of fibrinogen, d-dimer, vWF, TF and PAI-1 increased significantly after treatment with LT(4) for 1 year. Serum FT(4) was a significant predictor of increased fibrinogen, vWF and PAI-1 levels, when the data was controlled for age and BMI. CONCLUSIONS: Our results suggest that LT(4) suppression therapy for benign thyroid nodules is associated with enhanced coagulation.
Assuntos
Coagulação Sanguínea/efeitos dos fármacos , Regulação para Baixo , Nódulo da Glândula Tireoide/tratamento farmacológico , Tiroxina/administração & dosagem , Adulto , Estudos de Casos e Controles , Feminino , Fibrinogênio/metabolismo , Bócio , Humanos , Inibidor 1 de Ativador de Plasminogênio/sangue , Estudos Prospectivos , Nódulo da Glândula Tireoide/metabolismo , Nódulo da Glândula Tireoide/patologiaRESUMO
BACKGROUND: Insulin resistance is clearly associated with coronary artery disease (CAD) in diabetics. Insulin resistance may also be present in normoglycemic individuals, and some of these patients can be diagnosed as having metabolic syndrome (MS) according to various definitions. However, the relationship between hyperinsulinemia and CAD is obscure in normoglycemic individuals, especially in patients who do not meet the criteria for MS. HYPOTHESIS: This study evaluated insulin resistance in normoglycemic patients with CAD, and investigated the association of insulin resistance with inflammation and lipid levels. METHODS: Fifty-six CAD patients, and 57 age- and sex-matched controls with normal coronary arteries confirmed by conventional coronary arteries angiography were included in the study. Participants were considered for the diagnosis of MS according to criteria of the National Cholesterol Education Program (NCEPATP III) and the International Diabetes Federation (IDF). Fasting plasma glucose, insulin, lipids, and c-reactive protein (CRP) levels were studied. The homeostasis model assessment insulin resistance index (HOMA IR) was calculated. RESULTS: The ratio of subjects with MS was similar in the 2 groups. Insulin, CRP, low-density lipoprotein (LDL) cholesterol, and HOMA IR were higher in the study group than in the controls. The HOMA IR, LDL cholesterol, and serum CRP levels were determined as predictors of CAD. CONCLUSION: Our data revealed that insulin resistance and subclinical inflammation are present in normoglycemic patients with CAD. As the proportion of patients with MS was similar in the 2 groups, we suggest that HOMA IR values may provide more sensitive information than MS definitions about the association between insulin resistance and CAD in normoglycemic patients.
Assuntos
Glicemia/análise , Doença das Coronárias/sangue , Resistência à Insulina , Proteína C-Reativa/análise , LDL-Colesterol/sangue , Feminino , Homeostase , Humanos , Lipídeos/sangue , Masculino , Síndrome Metabólica/complicações , Pessoa de Meia-IdadeRESUMO
BACKGROUND: The constellation of truncal obesity, glucose intolerance, dyslipidemia (high triglycerides, low HDL cholesterol), and hypertension has been recognized as metabolic syndrome. However, the pathophysiological association between metabolic syndrome and erectile dysfunction (ED) has not yet been clearly determined. This study aimed to evaluate the penile Doppler ultrasound (PDU) findings of ED patients with metabolic syndrome. PATIENTS AND METHODS: Sixty-one age-matched ED patients with or without metabolic syndrome were included in the study. Patients were investigated by grouping according to risk factors of metabolic syndrome with PDU parameters (5th, 10th and 20th minute peak systolic velocity and end-diastolic velocity). PDU parameters of patients with and without metabolic syndrome were compared. RESULTS: The mean age of the patients were 54.9 +/- 8.3 and 54.9 +/- 7.6 years for the groups of with (n = 27) and without (n = 34) metabolic syndrome, respectively. When the mean peak flow velocities were compared with presence of metabolic syndrome, we observed differences between at the 5th, 10th and 20th minute peak systolic velocities (p = 0.083, p = 0.022 and p = 0.080, respectively). CONCLUSION: Metabolic syndrome seems to be the potential risk factor for ED, which may exert its effect by decreased arterial inflow due to endothelial dysfunction.
Assuntos
Impotência Vasculogênica/etiologia , Síndrome Metabólica/complicações , Ereção Peniana , Pênis/irrigação sanguínea , Pênis/fisiopatologia , Ultrassonografia Doppler , Idoso , Velocidade do Fluxo Sanguíneo , Estudos de Casos e Controles , Humanos , Impotência Vasculogênica/diagnóstico por imagem , Impotência Vasculogênica/fisiopatologia , Masculino , Síndrome Metabólica/diagnóstico por imagem , Síndrome Metabólica/fisiopatologia , Pessoa de Meia-Idade , Fluxo Sanguíneo RegionalRESUMO
OBJECTIVES: To determine the predominant pulmonary function abnormality in overweight and moderately obese subjects and to evaluate the correlation between the severity of lung function impairment and the degree of obesity. METHODS: Fifty-three volunteers underwent physical examination, skin fold measurements, and standardized pulmonary function tests. Thirty-one women and 22 men with a mean age of 40.2 (18-66) years were studied. RESULTS: The reduction in functional residual capacity (FRC) and expiratory reserve volume (ERV) were the most common abnormalities in overweight and obese subjects. The reduction in static lung volume was correlated with the degree of obesity in women and men. Stepwise multiple regression coefficients were obtained separately for women and men. Subscapular skinfold was the best predictor in women for FRC and waist-to-hip ratio (WHR) and BMI were found the best for ERV. WHR was found predictive for forced vital capacity, total lung capacity, and FRC in men. CONCLUSIONS: The lung volumes are substantially affected in our overweight and obese subjects. This influence is focused on different parameters of respiratory functions in men and women in relation to body fat distribution.
Assuntos
Distribuição da Gordura Corporal , Pneumopatias/etiologia , Obesidade/complicações , Obesidade/fisiopatologia , Adolescente , Adulto , Idoso , Estudos de Casos e Controles , Impedância Elétrica , Feminino , Humanos , Pneumopatias/fisiopatologia , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Sobrepeso/complicações , Sobrepeso/fisiopatologia , Análise de Regressão , Testes de Função Respiratória , Turquia , Relação Cintura-QuadrilRESUMO
OBJECTIVE: To evaluate subclinical inflammation and fibrinolysis in low-risk type 2 diabetic subjects and to assess the efficacy of metformin and rosiglitazone in this group. SUBJECTS AND METHODS: Sixty-one normotensive, normoalbuminuric type 2 diabetic subjects without diabetes-related complications were included in a 4-week standardization period with glimepiride. After the standardization period, 21 subjects were excluded and the remaining 40 were randomly divided into two groups matched for age, gender, body mass index and disease duration. The first group (n = 20) received metformin (1,700 mg/day), the second group (n = 20) rosiglitazone (4 mg/day) for 12 weeks. Patients with low-density lipoprotein-cholesterol higher than 130 mg/dl at the beginning of the randomization period were treated with simvastatin (maximum dose 20 mg/day). Twenty-three healthy controls were also recruited. Cytokine measurements were performed with ELISA kits. RESULTS: Baseline plasma plasminogen activator inhibitor-1 (PAI-1) level of type 2 diabetic subjects was significantly elevated (p = 0.038), but baseline levels of soluble CD40 ligand (sCD40L) and thrombin-activatable fibrinolysis inhibitor-1 (TAFI) antigen did not differ from healthy controls. Twelve weeks of metformin or rosiglitazone therapy did not cause significant changes in sCD40L, PAI-1 and TAFI antigen levels. In simvastatin-treated subjects (n = 9) significant reductions of PAI-1 were achieved (p = 0.028), while sCD40L and TAFI-Ag did not differ from baseline values. CONCLUSION: Our results showed that nonobese diabetic patients at low cardiovascular risk had similar levels of subclinical markers of inflammation and fibrinolysis as matched healthy controls. Neither metformin nor rosiglitazone caused marked changes in sCD40L, PAI-1 and TAFI antigen levels. A subset of patients who received simvastatin showed a modest decrease in PAI-1 level and could contribute to beneficial vasculoprotective effect of the drug in type 2 diabetics.
Assuntos
Ligante de CD40/metabolismo , Carboxipeptidase B2/metabolismo , Diabetes Mellitus Tipo 2/tratamento farmacológico , Hipoglicemiantes/uso terapêutico , Metformina/uso terapêutico , Inibidor 1 de Ativador de Plasminogênio/metabolismo , Tiazolidinedionas/uso terapêutico , Adulto , Idoso , Anticolesterolemiantes/uso terapêutico , Pressão Sanguínea/efeitos dos fármacos , LDL-Colesterol/sangue , Diabetes Mellitus Tipo 2/metabolismo , Diabetes Mellitus Tipo 2/fisiopatologia , Feminino , Fibrinólise , Humanos , Inflamação/metabolismo , Masculino , Pessoa de Meia-Idade , Rosiglitazona , Sinvastatina/uso terapêuticoRESUMO
Thyroid hemiagenesis is a rare anomaly due to failure of development of one thyroid lobe during embryological life. A lot of thyroid disorders may accompany thyroid hemiagenesis. In this report, we present a case of thyroid hemiagenesis, who had moderate hypercalcemia due to Graves' disease. A 43-year-old woman presented with weight loss of more than 5 kg within one month, heat intolerance, and increased sweating. For the past month, she had been troubled by intermittent symptoms of vomiting, thirst, and constipation. On examination, she had tachycardia with no signs of dehydration. Pulse rate was 110 per minute. She had fine tremor, proximal muscle weakness, and asymmetric smooth goiter and hyperplasia in the right thyroid gland. Thyroid function tests confirmed the diagnosis of hyperthyroidism. Although hypercalcemia may be detected in patients with thyrotoxicosis, to the best of our knowledge, this is the first case report of thyroid hemiagenesis accompanying hypercalcemia due to thyrotoxicosis.
Assuntos
Bócio/complicações , Doença de Graves/complicações , Hipercalcemia/etiologia , Glândula Tireoide/anormalidades , Adulto , Cálcio/sangue , Feminino , Doença de Graves/diagnóstico por imagem , Doença de Graves/fisiopatologia , Humanos , Hipertireoidismo/complicações , Hipertireoidismo/diagnóstico por imagem , Propranolol/uso terapêutico , Propiltiouracila/uso terapêutico , Cintilografia , Tecnécio Tc 99m Sestamibi/farmacocinética , Glândula Tireoide/diagnóstico por imagem , Ultrassonografia , Redução de PesoRESUMO
OBJECTIVE: Prediction of diabetic foot ulcer outcome may be helpful for clinicians in optimizing and individualizing management strategy. The aim of the present study was to examine the possibility of predicting the outcome of patients with diabetic foot ulcers by using easily assessed clinical and laboratory parameters at baseline. DESIGN: In this observational study, data were collected prospectively in 670 consecutive diabetic foot ulcer episodes in 510 patients examined between January 1999 and June 2008 and were used to evaluate potential predictors of amputation retrospectively. After exclusion of patients who did not come to the hospital for follow-up for a minimum of six months, data of 574 foot ulcer episodes were evaluated. RESULTS: Limb ischemia, osteomyelitis and presence of gangrene and ulcer depth, determined by the Wagner classification system, were the major independent predictors of overall and major amputations. Older age, presence of coronary artery disease, smoking and ulcer size were found to be associated with either overall or major amputations. Baseline levels of acute phase reactants (white blood cell count, polymorphonuclear leukocyte count, platelet count, erythrocyte sedimentation rate (ESR), serum C-reactive protein (CRP) and albumin) and decreased hemoglobin levels were associated with amputation risk. Multivariate analysis showed that one standard deviation increase in baseline CRP and ESR levels were independent predictors of overall and major amputations, respectively. CONCLUSIONS: The presence of limb ischemia, osteomyelitis, local and diffuse gangrene and ulcer depth were independent predictors of amputation. Baseline levels of ESR and CRP appeared to be helpful for clinicians in predicting amputation.
Assuntos
Amputação Cirúrgica , Proteína C-Reativa/metabolismo , Pé Diabético/cirurgia , Gangrena/complicações , Isquemia/complicações , Perna (Membro)/irrigação sanguínea , Osteomielite/complicações , Idoso , Sedimentação Sanguínea , Estudos de Coortes , Pé Diabético/sangue , Pé Diabético/etnologia , Feminino , Gangrena/diagnóstico , Humanos , Isquemia/diagnóstico , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Osteomielite/diagnóstico , Valor Preditivo dos Testes , Prognóstico , Estudos Prospectivos , Estudos Retrospectivos , Fatores de Risco , TurquiaRESUMO
BACKGROUND: Although the role of cytokines in the development of Hashimoto's thyroiditis has already been established, its pathogenesis has not yet been clearly elucidated. The aim of our study was to investigate serum transforming growth factor-beta1 (TGF-beta1) levels in patients with Hashimoto's thyroiditis as well as the effect of achieving euthyroidism by levothyroxine replacement on TGF-beta1 levels. METHODS: Twenty nine female, newly diagnosed hypothyroid Hashimoto's thyroiditis patients (16 overt, 13 subclinical hypothyroid) and 25 age- and sex-matched healthy controls were enrolled in the study. RESULTS: Serum TGF-beta1 levels were lower in the Hashimoto's thyroiditis group when compared with control cases. Although significant differences were noted in lipid levels and in anthropometric measurements following levothyroxine replacement, serum TGF-beta1 levels remained unchanged. CONCLUSIONS: Our data suggest that altered TGF-beta1 levels are associated with the presence of Hashimoto's thyroiditis, not with the treatment of thyroid dysfunction. Autoimmunity may have been triggered as a result of decreased immunosuppressive effect induced by depressed TGF-beta1 levels in patients with Hashimoto's thyroiditis.
Assuntos
Doença de Hashimoto/sangue , Doença de Hashimoto/tratamento farmacológico , Hipotireoidismo/tratamento farmacológico , Tiroxina/uso terapêutico , Fator de Crescimento Transformador beta1/sangue , Adulto , Feminino , Humanos , Hipotireoidismo/sangue , Pessoa de Meia-Idade , Tiroxina/administração & dosagemRESUMO
OBJECTIVES: To describe a patient who was misdiagnosed as having a nonfunctional pituitary tumor due to the hook effect on prolactin measurements. CLINICAL PRESENTATION AND INTERVENTION: A 45-year-old female was admitted with visual disturbances, panhypopituitarism and central diabetes insipidus due to pituitary tumor recurrence. She had been operated 4 times earlier and received cranial irradiation for a suspected nonfunctional pituitary adenoma. Serum prolactin was moderately elevated (164.5 ng/ml), but increased markedly after 1:100 dilution to 14,640 ng/ml. Diagnosis of a giant macroprolactinoma was made and cabergoline was started. Prolactin level normalized and a mild shrinkage of the tumor was achieved after 12 months of therapy. CONCLUSION: The hook effect must be kept in mind while evaluating a giant pituitary adenoma with moderately elevated prolactin levels. This way unnecessary surgical procedures or irradiation may be avoided.
Assuntos
Erros de Diagnóstico , Recidiva Local de Neoplasia/complicações , Neoplasias Hipofisárias/diagnóstico , Prolactina/sangue , Prolactinoma/diagnóstico , Antineoplásicos , Cabergolina , Diabetes Insípido Neurogênico/etiologia , Ergolinas/uso terapêutico , Feminino , Glucocorticoides/uso terapêutico , Humanos , Hipopituitarismo/etiologia , Pessoa de Meia-Idade , Neoplasias Hipofisárias/sangue , Neoplasias Hipofisárias/complicações , Prednisolona/uso terapêutico , Prolactinoma/sangue , Prolactinoma/complicações , Tiroxina/uso terapêuticoRESUMO
OBJECTIVES: This prospective study was designed to investigate the effect of levothyroxine suppression therapy for benign thyroid nodules on markers of bone turnover in premenopausal women. PATIENTS AND METHODS: The study included 28 premenopausal women who received levothyroxine suppression therapy for benign thyroid nodules for one year. The size of the thyroid gland and nodules, biochemical markers of bone turnover and urinary calcium excretion were measured before and after levothyroxine suppression therapy. RESULTS: No significant adverse effects were seen during levothyroxine treatment. Decreases in total thyroid volume and the size of the nodules were not significant at the end of treatment. Although levothyroxine suppression therapy did not result in changes in serum levels of calcium and phosphor, and urinary calcium excretion, bone turnover markers, namely serum osteocalcin and urinary deoxypyridinoline levels, increased significantly. Serum intact parathyroid hormone levels showed a minimal decrease, which was not statistically significant. CONCLUSION: Data from our study suggest that levothyroxine suppression therapy is associated with increased osteoblastic and osteoclastic activity in premenopausal women with benign thyroid nodules.
Assuntos
Osso e Ossos/metabolismo , Pré-Menopausa , Nódulo da Glândula Tireoide/tratamento farmacológico , Tiroxina/uso terapêutico , Aminoácidos/urina , Biomarcadores , Osso e Ossos/efeitos dos fármacos , Cálcio/sangue , Cálcio/urina , Feminino , Humanos , Osteocalcina/sangue , Osteocalcina/efeitos dos fármacos , Hormônio Paratireóideo/sangue , Fósforo/sangue , Estudos Prospectivos , Glândula Tireoide/anatomia & histologia , Glândula Tireoide/efeitos dos fármacos , Tiroxina/efeitos adversosRESUMO
It is widely known that metformin reduces the levels of circulating pro-coagulant factors and improve fibrinolytic activity in type 2 diabetes when used in therapeutic doses. Potential alterations of coagulation have not been reported in patients with metformin intoxication. We evaluated certain components of the coagulation system in a patient with metformin intoxication upon admission and after recovery. Our results indicate that both the levels of coagulation proteins synthesized by the liver and the anti-coagulant activity decrease temporarily in metformin intoxication. Nevertheless, no change in the coagulation factors secreted by the endothelium were observed.
Assuntos
Coagulação Sanguínea/efeitos dos fármacos , Metformina/intoxicação , Intoxicação/sangue , Tentativa de Suicídio , Acidose/etiologia , Acidose/terapia , Feminino , Humanos , Hipoglicemiantes/intoxicação , Bombas de Infusão , Intoxicação/complicações , Intoxicação/terapia , Diálise Renal , Bicarbonato de Sódio/administração & dosagem , Adulto JovemRESUMO
OBJECTIVE: a)To determine serum Transforming Growth Factor-beta 1 (TGF-beta 1) levels in patients with type 2 diabetes who do not have diabetes related complications and in healthy controls, b) to evaluate the effects of metformin and rosiglitazone on TGF-beta 1 levels. DESIGN: In the washout period, 61 patients with Fasting Plasma Glucose levels (FPG) higher than 140 mg/dl, Postprandial Glucose (PPG) levels higher than 180 mg/dl and A1c levels exceeding 6.5% were treated with glimperide. After 4 weeks, 39 of these patients were randomised to receive either metformin or rosiglitazone for 12 weeks. Thirty healthy controls were also studied. RESULTS: There were no significant differences with regard to age, gender, body weight and BMI between patients and healthy controls. Type 2 diabetics had higher waist circumference, FPG, total cholesterol, LDL-cholesterol and triglyceride levels. Baseline TGF-beta 1 levels in diabetics were higher than in controls (29.84+/-7.04 ng/ml vs 11.37+/-4.06 ng/ml, p<0.001). Metformin or rosiglitazone did not significantly modify the TGF-beta 1 levels. In a multiple regression analysis FPG was the only variable that was significantly associated with plasma TGF-beta 1 levels. CONCLUSION: The elevated levels of TGF-beta 1 in subjects with type 2 diabetes possibly indicate a tendency for renal and endothelial damage in such patients. The association of TGF-beta 1 with FPG possibly links poor diabetic control to vascular damage, leading to diabetic complications. Lack of changes in the levels of TGF-beta 1 after therapy may reflect inadequate therapy duration.
Assuntos
Diabetes Mellitus Tipo 2/sangue , Diabetes Mellitus Tipo 2/tratamento farmacológico , Hipoglicemiantes/uso terapêutico , Metformina/uso terapêutico , Tiazolidinedionas/uso terapêutico , Fator de Crescimento Transformador beta1/sangue , Adulto , Idoso , Glicemia/metabolismo , Pressão Sanguínea/fisiologia , Índice de Massa Corporal , Feminino , Hemoglobinas Glicadas/análise , Hemoglobinas Glicadas/metabolismo , Humanos , Lipídeos/sangue , Masculino , Pessoa de Meia-Idade , Análise de Regressão , Rosiglitazona , Albumina Sérica/metabolismoRESUMO
Amelanotic melanoma often leads to delayed clinical diagnosis because of its wide range of clinical appearances and lack of pigmentation. Misdiagnosis of amelanotic melanoma is also common, particularly when it is located at the foot. We report here a 71-year-old male patient with a 17-year history of type 2 diabetes mellitus who presented with a small ulcer under his fifth metatarsal head, which was previously misdiagnosed as a diabetic foot ulcer. The patient was treated with local wound care and systemic antibiotics without any improvement of the ulcer. Further investigation of the patient in our clinic revealed plantar amelanotic melanoma.
Assuntos
Pé Diabético/diagnóstico , Melanoma Amelanótico/diagnóstico , Neoplasias Cutâneas/diagnóstico , Idoso , Angiopatias Diabéticas/diagnóstico , Pé Diabético/patologia , Erros de Diagnóstico , Hemoglobinas Glicadas/metabolismo , Humanos , Masculino , Melanoma Amelanótico/patologia , Neoplasias Cutâneas/patologiaRESUMO
OBJECTIVE: The purpose of this study was to determine thiobarbituric acid-reactive substance (TBARS) levels in subclinical hypothyroidism and to examine the effect of levothyroxine replacement on TBARS levels. SUBJECTS AND METHODS: A cohort of 28 female patients with subclinical hypothyroidism and 24 healthy controls were enrolled in this study. The levels of plasma TBARS, serum lipids, and high-sensitive C-reactive protein (CRP) in patients with subclinical hypothyroidism at baseline and after achieving euthyroid state by levothyroxine were assessed. RESULTS: TBARS levels of the patients were similar to those of the control group in the subclinical hypothyroid state and after restoration of euthyroidism by levothyroxine replacement. TBARS levels decreased after levothyroxine treatment, but did not reach statistical significance. There was no significant correlation between TBARS, lipid and CRP levels. Serum CRP levels were higher in subclinical hypothyroidism (4.28 +/- 0.9 mg/l) than in the control group (1.95 +/- 0.34 mg/l) and the difference was statistically significant (p = 0.03). After achieving euthyroid state, CRP levels decreased significantly in patients with subclinical hypothyroidism from 4.28 +/- 0.9 to 2.32 +/- 0.6 mg/l (p = 0.006). CONCLUSION: Our findings suggest that there is no significant alteration of plasma TBARS levels neither in subclinical hypothyroid state nor after achieving euthyroid state. Serum CRP level is higher in patients with subclinical hypothyroidism than in the control group. Normalization of thyroid state seems to effectively reduce serum CRP levels in subclinical hypothyroidism without any correlation with TBARS activity.
Assuntos
Hipotireoidismo/sangue , Substâncias Reativas com Ácido Tiobarbitúrico/metabolismo , Adulto , Proteína C-Reativa/metabolismo , Estudos de Casos e Controles , Estudos de Coortes , Feminino , Humanos , Hipotireoidismo/tratamento farmacológico , Lipídeos/sangue , Pessoa de Meia-Idade , Estresse Oxidativo/fisiologia , Tiroxina/uso terapêuticoRESUMO
OBJECTIVE: There is controversy as to whether hypothyroidism increases cardiovascular risk. The effect of levothyroxine on the cardiovascular risk profile is also unclear. Recent studies suggest that there is evidence of inflammation and endothelial dysfunction in hypothyroidism. Soluble CD40 ligand (sCD40L) is a protein expressed mainly by activated platelets which have been found to be associated with cardiovascular events. The aim of our study was to investigate serum sCD40L levels and the effect of levothyroxine replacement on sCD40L levels in overt and subclinical hypothyroidism. DESIGN: We assessed lipid profile, serum sCD40L and hsCRP levels in 21 overt and 22 subclinical hypothyroid age-matched female patients with chronic autoimmune thyroiditis at baseline and one month after achieving euthyroidism by levothyroxine replacement, and compared them with the data from 22, age-matched, healthy controls. RESULTS: Overt and subclinical hypothyroid patients had decreased sCD40L levels compared to age-matched controls. The patients with subclinical hypothyroidism had slightly increased hsCRP levels, but the result was not statistically significant. In multiple regression analysis, FT3 and FT4 were found to be independent predictors of sCD40L levels. After levothyroxine replacement, serum sCD40L levels increased significantly in the patients with overt hypothyroidism. Although an increase was also observed in the subclinical hypothyroid group, it was not statistically significant. Levothyroxine replacement had no significant effect on hsCRP levels in the patients with overt hypothyroidism. However, the subjects with subclinical hypothyroidism showed a significant reduction in hsCRP levels after levothyroxine. CONCLUSION: The values of sCD40L and hsCRP in our study suggest that inflammatory pathways are complex and may be affected by different factors in hypothyroidism.